DDInter1676 DDInter1032
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.
Lefamulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lefamulin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Octreotide
Lefamulin may lead to a major life threatening interaction when taken with Vandetanib
Lefamulin may lead to a major life threatening interaction when taken with Macimorelin